Every Cure, a nonprofit biotech organization dedicated to saving and improving lives through drug repurposing, today announced a partnership with OpenEvidence, the most popular AI for doctors in the United States, to turn existing medicines into new treatments for patients who have run out of options. By connecting Every Cure’s AI-driven engine with OpenEvidence’s proprietary AI models and its nationwide reach among physicians, the collaboration will support the full path of repurposing, focusing on areas where there is no commercial incentive to repurpose the medicine. OpenEvidence will help Every Cure evaluate therapeutic hypotheses, match patients to trials, and disseminate evidence at the point of care, bringing promising treatments to patients sooner.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116021743/en/

Every Cure and OpenEvidence partner to repurpose drugs where commercial incentives fall short.

Every Cure and OpenEvidence partner to repurpose drugs where commercial incentives fall short.

Thousands of human diseases have no FDA-approved treatment, yet some of the answers may already be sitting on pharmacy shelves. Because approved medicines have known safety profiles and are already manufactured, a repurposed drug can reach patients far sooner than a new drug, which can take billions of dollars and over 10 years to develop. Every Cure co-founder and CEO David Fajgenbaum, MD, a 2025 TIME100 Health honoree, nearly died of idiopathic multicentric Castleman disease and was told there were no options left. He found an overactive immune pathway in his blood and tested sirolimus, a decades-old drug approved to prevent rejection after kidney transplants, which targets the same pathway. He has been in remission for more than a decade and co-founded Every Cure to make discoveries like his systematic. Many promising candidates involve generic drugs with no commercial incentive for repurposing, and as a nonprofit, Every Cure is built to pursue them.

Drawing on its frontier AI technology and proprietary biomedical sources and data, including its strategic content partnership with Nature journals, OpenEvidence will help Every Cure evaluate promising repurposing hypotheses. Validating each candidate also requires input from physicians with firsthand experience caring for patients with the disease, who understand how it progresses, where current treatments fall short, and what matters most to patients. For many rare and underserved diseases, only a small number of these physicians exist. As the medical AI platform used daily, on average, by the majority of physicians in the United States, OpenEvidence will match Every Cure’s repurposing programs with the clinicians who can bring these insights into the research.

Once Every Cure identifies a promising repurposing opportunity, it generates the evidence needed to determine whether the treatment is safe and effective in the new disease, and then works to remove any barriers that would keep patients from accessing it. OpenEvidence will continue to support Every Cure as its programs move from research to the clinic. When programs advance into clinical trials, OpenEvidence will help locate eligible patients wherever they are, which matters most in rare diseases, where recruitment is often particularly difficult. OpenEvidence will flag when a patient may qualify for a trial, letting the treating physician decide whether to pursue the referral. As results emerge from Every Cure’s trials, OpenEvidence will disseminate those findings to physicians at the point of care, allowing validated treatments to reach patients sooner.

This partnership deepens OpenEvidence’s commitment to rare diseases, which includes more than 3,000 expert-reviewed rare disease summaries developed with the National Organization for Rare Disorders (NORD). Founded with the mission to organize and expand the world’s collective medical knowledge and to help doctors save lives, OpenEvidence will now support Every Cure in bringing new therapies to patients still waiting for a breakthrough.

“Some of the most promising new uses for existing medicines are in diseases that few physicians ever see,” said Matt Goddeeris, PhD, Chief Scientific Officer of Every Cure. “OpenEvidence can help us reach the physicians who care for these patients. Moreover, their firsthand experience will help us ask better research questions and design studies that address what matters most to patients and physicians.”

“Physicians come to OpenEvidence for the best available evidence, but for thousands of diseases, that evidence doesn’t exist yet,” said Isabel Ostrer, MD, Director of Primary Care Initiatives at OpenEvidence. “Together with Every Cure, we can generate hypotheses and evidence to help patients who have exhausted all treatment options.”

About Every Cure

Every Cure is a nonprofit biotech organization dedicated to saving and improving lives by repurposing drugs. Founded on pioneering drug repurposing research conducted at the University of Pennsylvania, Every Cure uses advanced data science and AI-driven approaches to systematically evaluate all approved drugs against all diseases. This comprehensive strategy helps uncover the most promising and efficient opportunities for helping people—particularly those with rare, neglected, and underserved conditions. By accelerating drug repurposing, Every Cure aims to deliver safer, faster, and more affordable treatments to patients who currently have limited or no options. For more information, visit everycure.org.

About OpenEvidence

OpenEvidence is the most popular AI for doctors in the United States. According to independent studies, more American physicians use OpenEvidence than all other AI platforms combined. OpenEvidence is trusted by millions of verified U.S. healthcare professionals making high-stakes clinical decisions at the point of care, with evidence that is sourced, cited, and grounded in peer-reviewed medical literature. Founded with the mission to organize and expand the world’s collective medical knowledge, OpenEvidence is now used daily, on average, by the majority of physicians in the United States. OpenEvidence is free for all verified U.S. clinicians. Learn more at openevidence.com.

Media gallery

About The Author